SCF ENCYCLOPEDIA ENTRY

WEST NILE VIRUS (WNV)

I. SCOPE & POSITIONING

Pathogen / Etiology: West Nile virus

Classification: Viral (Flaviviridae family; positive-sense single-stranded RNA virus)

Transmission:

• Mosquito bite (primarily Culex species)
• Bird–mosquito transmission cycle (humans are incidental hosts)
• Rare:
• Blood transfusion
• Organ transplant

Primary Tropism:

• Initially: blood and lymphatic system
• Severe cases: central nervous system (CNS)

SCF Classification:

Vector-Borne Neurotropic Immune-Modulated Biphasic Viral Inflammatory Neuroinvasive Disorder (VNIM-BVNIND Class)

II. GLOBAL & CLINICAL SIGNIFICANCE

• Widely distributed (Africa, Europe, Americas, Middle East)
• Seasonal (summer–fall; mosquito activity)

Clinical Distribution:

• ~80% asymptomatic
• ~20% mild febrile illness
• <1% severe neuroinvasive disease

Clinical Hallmarks:

• Fever
• Headache
• Fatigue

Severe Complications:

• Encephalitis
• Meningitis
• Acute flaccid paralysis (polio-like)

Aligned SCF Clinical Domains:

• C3: Neuroimmune Systems
• C2: Infectious & Inflammatory Medicine
• C12: Vector-Borne Viral Diseases

III. ETIOPATHOGENIC CORE

Primary Mechanisms:

1. Mosquito inoculation
2. Local replication in skin
3. Viremia
4. Possible CNS invasion

Key Drivers:

• Neurotropism (in severe cases)
• Immune response variability
• Blood–brain barrier permeability

IV. SCF FAULT ARCHITECTURE

Key Insight:

West Nile virus is a probabilistic neuroinvasive disease, where:

• Most infections remain mild
• A subset progresses to CNS involvement based on host factors

V. MULTI-OMICS PATHOGENESIS MAP (Neuroinvasive Flavivirus Model)

A. Genomics

• RNA genome with strain variability
• Mutations influence virulence and neuroinvasiveness

B. Transcriptomics

• Host immune gene activation
• Cytokine signaling pathways

C. Proteomics

• Envelope (E) protein:
• Mediates cell entry
• Nonstructural proteins:
• Facilitate replication
• Suppress immune response

D. Epigenomics

• Immune regulation changes
• Neuroinflammatory gene activation

E. Metabolomics

• Altered neuronal metabolism
• Energy deficits in CNS

F. Interactomics

• Virus–immune system interactions
• Virus–neuron interactions

G. Neurovascular Interface

• Blood–brain barrier disruption
• Neuroinflammation
• Neuronal injury

VI. PATHOGENESIS FLOW (SCF LOGIC)

Mosquito bite → Local replication → Viremia → Immune response → (subset) CNS invasion → Neuroinflammation → Neurological dysfunction

VII. CLINICAL SPECTRUM

1. ASYMPTOMATIC

• No symptoms
• Most common outcome

2. WEST NILE FEVER (MILD)

Features:

• Fever
• Fatigue
• Myalgia

3. NEUROINVASIVE DISEASE

Features:

• Encephalitis
• Meningitis
• Paralysis

Risk Factors for Severe Disease:

• Older age
• Immunocompromised state

VIII. SCF DISEASE-ORIGIN MODEL

A. Core Mechanisms:

• Viral replication
• Immune response
• CNS invasion (in severe cases)

B. SCF Classification:

• Primary: Vector-Borne Viral Infection
• Secondary: Neuroinflammatory Disorder

IX. SCF TRINITY FRAMEWORK MAPPING

Interpretation:

West Nile virus represents a threshold-based neuroinvasion model, where disease severity depends on the balance between viral load and immune control.

X. SCF PCR THERAPEUTIC STRATEGY

1. PREVENTATIVE (P)

• Mosquito control
• Protective clothing
• Insect repellents

2. CURATIVE (C)

• No specific antiviral therapy

Supportive Care:

• Hydration
• Pain management
• Hospitalization (severe cases)

3. RESTORATIVE (R)

• Neurological rehabilitation
• Long-term recovery support
• Monitoring for persistent deficits

XI. CURRENT STANDARD OF CARE

• Supportive management only
• Prevention via vector control

XII. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

High-Value Targets:

• Viral entry mechanisms
• Blood–brain barrier crossing
• Neuroinflammatory pathways

SCF Design Strategy:

• Neuroprotective antivirals
• BBB-stabilizing agents
• Immune modulation therapies

XIII. RHENOVA INTEGRATION (REDOX–HYPOXIA LOGIC)

Core Disruption:

• CNS inflammation → oxidative stress
• Neuronal hypoxia
• Mitochondrial dysfunction

SCF–RHENOVA Role:

• Monitor neuro-metabolic stress
• Predict long-term neurological outcomes
• Guide recovery

XIV. TRANSLATIONAL BLUEPRINT (FDA-ALIGNED)

Preclinical:

• Flavivirus models
• Neuroinvasion studies

Clinical:

• Risk stratification
• Early detection of CNS involvement
• Long-term neurological monitoring

Biomarkers:

• West Nile IgM antibodies (CSF/serum)
• PCR (early phase)
• CSF pleocytosis

XV. SCF DBI INTERPRETATION

Insight:

West Nile virus represents a DBI conditional neuroinvasion model, where only certain host–pathogen interactions lead to severe disease.

XVI. SCF LAYMAN’S TRANSLATION SUMMARY

West Nile virus is a mosquito-borne infection.

Most people:

• Have no symptoms or mild illness

In rare cases, it:

• Affects the brain and nervous system
• Can cause serious complications

SCF treatment focuses on:

• Preventing mosquito bites
• Supporting the body during illness
• Helping recovery if the brain is affected

XVII. MASTER REGISTRY INDEX

• SCF-VIR-WNV-0001 — West Nile Entry
• SCF-FLAVIVIRUS-0002 — Viral Module
• SCF-NEURO-0003 — CNS Registry
• SCF-RHENOVA-NEURO-0004 — Brain Mapping
• SCF-DBI-THRESHOLD-0005 — Neuroinvasion Model

NEXT STEP OPTIONS

If you want to go deeper, I can generate:

• SCF comparison: West Nile vs Zika vs Dengue vs TBE
• API discovery targeting flavivirus neuroinvasion pathways
• BBB-protection therapeutic platform (SCF)
• Post-viral neurological recovery protocol (SCF)